Neurturin has failed to demonstrate any effect in Parkinson's Disease. Neurturin is administered using CERE-120, which is composed of a harmless adeno-associated virus (AAV) vector, which carries the gene for neurturin. Neurturin, which is naturally occurring, is known to repair damaged and dopamine-secreting neurons by restoring their function. Neurturin is a member of the same protein family as GDNF. CERE-120 is delivered by injection in to the brain. CERE-120 is produced by Ceregene Inc.
The clinical trial did not demonstrate statistically significant efficacy. Yet, following surgery, there was a marked placebo effect in those people being tested and even those not being tested, as there often is after surgical trials. The clinical trial was supported by the Michael J.Fox Foundation. The results suggest that it is unclear if Ceregene will move forward with the development of CERE-120 as a viable treatment for people with Parkinson’s Disease. 
No comments:
Post a Comment